Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | GSK3A | P49840 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 2/20 | 0.51 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.50 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 2/20 | 0.49 |
| ▸ | BCL2 | P10415 | 2/20 | 0.49 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.49 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.49 |
| ▸ | BAD | Q92934 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3426761 | 1.00 | ALDH1A1 (0.62) | ALDH1A1PKMGAAMAPTKMT2A | |
| SCHEMBL13576559 | 0.86 | ALDH1A1 (0.66) | ALDH1A1PKMGAAMAPTKMT2A | |
| SCHEMBL10889528 | 0.78 | KMT2A (0.64) | ALDH1A1GAAMAPTKMT2AMEN1 | |
| SCHEMBL7249823 | 0.78 | KMT2A (0.59) | ALDH1A1GAAMAPTKMT2AMEN1 | |
| SCHEMBL2304471 | 0.77 | ALDH1A1 (1.00) | ALDH1A1PKMGAAMAPTKMT2A | |
| SCHEMBL1563867 | 0.77 | ALDH1A1 (1.00) | ALDH1A1PKMGAAMAPTKMT2A | |
| SCHEMBL28622320 | 0.77 | KMT2A (0.58) | ALDH1A1GAAMAPTKMT2AMEN1 | |
| SCHEMBL6386661 | 0.76 | ALDH1A1 (0.90) | ALDH1A1PKMGAAMAPTKMT2A | |
| SCHEMBL3423470 | 0.75 | KMT2A (0.65) | ALDH1A1GAAMAPTKMT2AMEN1 | |
| SCHEMBL6888295 | 0.75 | KMT2A (0.56) | ALDH1A1GAAMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507546-B2 | Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2013-08-13 | — | — | US | disclosed |
| US-8507546-B2 | Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2013-08-13 | — | — | US | disclosed |
| EP-1313731-B1 | THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT | UCB SA (BE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010024783-A1 | BIARYLRHODANINE AND PYRIDYLRHODANINE COMPOUNDS AND THEIR USE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-03-04 | — | — | WO | disclosed |
| EP-1313471-B1 | BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS | UCB SA (BE) | 2007-04-11 | — | — | EP | disclosed |
| US-7105554-B2 | Benzylidene thiazolidinediones and their use as antimycotic agents | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2006-09-12 | — | — | US | disclosed |
| US-6740670-B2 | SUCH AS 5-(((3-(N-METHYL-N-PHENYLAMINO)CARBONYL-4-(PHENYL-METHOXY)) -PHENYL)METHYLENE)-4-OXO-2-THIOXO-3-THIAZOLIDINE-ACETIC ACID | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2004-05-25 | — | — | US | disclosed |
| US-20040006112-A1 | Benzylidene thiazolidinediones and their use as antimycotic agents | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2004-01-08 | — | — | US | disclosed |
| US-20030216453-A1 | Thiazolidine derivatives and its use as antifungal agent | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2003-11-20 | — | — | US | disclosed |
| EP-1313731-A1 | THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT | Oxford GlycoSciences (UK) Limited (GB) | 2003-05-28 | — | — | EP | disclosed |
| US-6506755-B2 | 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis | HOFFMANN-LA ROCHE INC. | 2003-01-14 | — | — | US | disclosed |
| US-20020037901-A1 | Thiazolidinecarboxyl acids | HOFFMANN-LA ROCHE INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1189894-A1 | THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-27 | — | — | EP | disclosed |
| WO-2002022612-A1 | THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT | OXFORD GLYCOSCIENCES (UK) LIMITED (GB) | 2002-03-21 | — | — | WO | disclosed |
| WO-2001057006-A1 | THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-09 | — | — | WO | disclosed |
| US-4804599-A | BENZOTHIAZOLE OR BEXZOSELENAZOLE HOLOGRAPHIC MATERIALS | CIBA-GEIGY AG (SE) | 1989-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216453-A1 | Thiazolidine derivatives and its use as antifungal agent | CYP3A7, TAS2R7, OXSR1 | ALDH1A1 2527/4885PKM 3342/4885GAA 2941/4885 |
| US-20020037901-A1 | Thiazolidinecarboxyl acids | TPMT, NAT1, THRA | ALDH1A1 27/4885PKM 3627/4885GAA 3102/4885 |
| US-20040006112-A1 | Benzylidene thiazolidinediones and their use as antimycotic agents | SLC5A2, OXSR1, SLC5A1 | ALDH1A1 2757/4885PKM 2607/4885GAA 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.